Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.56 |
| ▸ | FAAH | O00519 | 5/20 | 0.56 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.54 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 3/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.52 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.52 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346341 | 1.00 | EPHX2 (0.56) | EPHX2FAAHP2RY10GPR174CNR1 | |
| SCHEMBL24340372 | 0.94 | ASAH1 (0.58) | EPHX2FAAHP2RY10GPR174CNR1 | |
| SCHEMBL24340370 | 0.94 | ASAH1 (0.58) | EPHX2FAAHP2RY10GPR174CNR1 | |
| SCHEMBL23373452 | 0.87 | ASAH1 (0.51) | EPHX2CNR1ASAH1MEN1KMT2A | |
| SCHEMBL6348309 | 0.85 | EPHX2 (0.51) | EPHX2FAAHCNR1CNR2SOAT2 | |
| SCHEMBL6348306 | 0.85 | EPHX2 (0.51) | EPHX2FAAHCNR1CNR2SOAT2 | |
| SCHEMBL6346850 | 0.83 | DGKA (0.60) | FAAHP2RY10GPR174LPAR1 | |
| SCHEMBL6346855 | 0.83 | DGKA (0.60) | FAAHP2RY10GPR174LPAR1 | |
| SCHEMBL28799819 | 0.81 | ASAH1 (0.47) | EPHX2ASAH1 | |
| SCHEMBL5415667 | 0.80 | ASAH1 (0.41) | EPHX2SOAT1ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911553-B1 | Osteoblast-specific mitogens and drugs containing such compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | ESSWEIN ANGELIKA (DE) | 2005-01-20 | — | — | US | disclosed |
| US-6197759-B1 | ADMINISTERING LYSOPHOSPHATIDYLIC ACID DERIVATIVE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
| EP-0906759-A1 | Novel osteoblastic specific mitogenes: process for their preparation and drugs containing these compounds | Roche Diagnostics GmbH (DE) | 1999-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | LPAR1, LPAR2, LPAR4 | EPHX2 84/4885FAAH 531/4885P2RY10 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.